Core Event - Heng Rui Medicine received the acceptance notice from the National Medical Products Administration for the marketing authorization application of the innovative drug injection of Carrelizumab combined with Apalutamide capsules for first-line treatment of recurrent or metastatic cervical cancer patients [1] Clinical Trial Data - Trial Design: Phase III randomized controlled multicenter study involving 45 domestic centers with 443 patients enrolled [2] - Trial Results: The trial met its primary endpoint, with the experimental group showing significantly better progression-free survival (PFS) and overall survival (OS) compared to the control group [2] Market Background - Indication: Cervical cancer has the highest incidence and mortality rates among female reproductive system tumors in China, indicating an unmet clinical need [2] - Competitive Landscape: The global sales of anti-PD-1 antibodies are projected to reach approximately $41.546 billion in 2024 [2] R&D Investment - Cumulative R&D investment in Carrelizumab is approximately 3.026 billion yuan [2] - Cumulative R&D investment in Apalutamide is approximately 258 million yuan [2]

Core Viewpoint - Fosun Pharma's subsidiary, Fuhong Hanlin, has received approval from the National Medical Products Administration to conduct clinical trials for HLX43 in combination with HLX07 for the treatment of advanced/metastatic solid tumors [1] Group 1: Clinical Trial Approval - The approved clinical trial will focus on the combination of HLX43, a novel DNA topoisomerase I inhibitor, and HLX07, an innovative biological drug targeting EGFR, for treating advanced/metastatic solid tumors [1] - The clinical trials are planned to be conducted in China once conditions are met [1] Group 2: Financial Investment - As of August 2025, the cumulative R&D investment for this treatment plan is approximately RMB 150,000 [1] Group 3: Market Context - There are currently no similar combination therapies approved for market globally [1]

Core Viewpoint - The announcement highlights the approval of a clinical trial application for UBT37034, a novel peptide receptor agonist targeting overweight or obesity, indicating a significant advancement in the company's product pipeline and potential market competitiveness [1] Group 1: Clinical Trial Approval - The clinical trial registration application for UBT37034 received implied approval from the National Medical Products Administration of China, with acceptance number CXHL2500772 [1] - UBT37034 is designed to selectively act on the neuropeptide Y2 receptor to aid in weight reduction [1] Group 2: Preclinical and Regulatory Milestones - Preclinical studies in various animal models demonstrated that UBT37034, in combination with GLP-1 analogs, can significantly reduce body weight [1] - The Investigational New Drug (IND) application for UBT37034 was approved by the U.S. Food and Drug Administration on July 2025, with IND number 175188 [1] Group 3: Future Outlook - The company aims to continue its focus on new product development to enhance its competitiveness and creativity in the biopharmaceutical industry [1] - There is an expectation that these advancements will generate greater returns for the company and its shareholders [1]

Core Insights - A large number of medical companies, including Aikobio, are applying for listings on the Hong Kong Stock Exchange, indicating a trend in the healthcare sector [1] - Aikobio has previously attempted to list on the Hong Kong Stock Exchange and has shifted its focus to the A-share market, but later withdrew its application due to strategic considerations [2][3] - The company has a dual-track drug development strategy, combining both in-house research and external collaborations [8] Company Overview - Aikobio was founded in August 2013 and became a joint-stock company in March 2021, headquartered in Shanghai [5] - The company has received multiple rounds of investment from notable investors such as Hillhouse Capital and Qiming Venture Partners [5] - As of June 2025, the founder, Dr. Wu Zheng, controls 25.17% of the company and has a strong background in pharmaceutical research [6] Product Pipeline - Aikobio has developed six candidate drugs, including AK0529, which targets respiratory syncytial virus (RSV) and is in the NDA stage [10] - The company’s core product, AK0529, is the first RSV-specific antiviral drug to show positive results in pivotal Phase III trials [18] - Another key product, AK3280, is in Phase II and targets idiopathic pulmonary fibrosis (IPF), with a significant market potential projected to grow from $6.9 billion in 2024 to $22.2 billion by 2035 [23] Financial Performance - Aikobio has not yet commercialized any products and reported cumulative losses of 570 million RMB over two and a half years [28] - The company’s revenue primarily comes from a collaboration on a hepatitis B virus candidate drug, but this project has been paused [28] - As of December 2025, the company had approximately 96.73 million RMB in cash and cash equivalents, which is expected to sustain its operations for about 16 months at the current burn rate [30]

2025 年 9 月 29 日，四川百利天恒药业股份有限公司召开相关会议，审议通过使用部分募集资金向全资 子公司实缴出资以实施募投项目的议案。公司向特定对象发行股票，实际募集资金净额 3,731,054,180.03 元，将全部用于创新药研发项目。公司拟将该笔资金及结息通过百利药业向多特生物 增资，部分计入注册资本，部分计入资本公积。本次增资不构成关联交易与重大资产重组，在董事会审 批权限内。保荐人认为该事项履行必要程序，符合相关要求，无异议。增资有助于推进项目建设，子公 司将依规管理募集资金。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司 本公告乃由聯邦制藥國際控股有限公司（「本公司」）自願發出。 本公司董事會欣然公佈，於二零二五年九月二十九日，本公司全資附屬公司聯邦生物科技 （珠海橫琴）有限公司自主研發的 1 類創新藥注射用 UBT37034 關於超重或肥胖適應症的 臨 床 試 驗 註 冊 申 請 獲 得 中 國 國 家 藥 品 監 督 管 理 局 臨 床 試 驗 默 示 許 可 ， 受 理 號 為 CXHL2500772。 UBT37034 是一款新型多肽類受體激動劑，可通過選擇性作用於神經肽 Y2 受體減輕體重。 臨床前多種動物模型研究結果顯示，UBT37034 與 GLP-1 類似物聯用能夠顯著降低體重。 此外，UBT37034 注射液關於超重或肥胖適應症的新藥臨床試驗申請（「IND」）已於二零二 ...

Group 1 - The core viewpoint is that the collaboration between China and the US in innovation is expected to continue, with a recovery in domestic innovation and R&D demand in China [1][2] - The MSCI China Healthcare Index has increased by 74.0% since the beginning of 2025, outperforming the MSCI China Index by 37.3% [1] - The price for experimental monkeys, essential for innovative drug R&D, has risen from approximately 85,000 yuan in mid-2024 to about 90,000 yuan [1] Group 2 - The US is expected to impose tariffs on innovative drugs, but the impact on the CXO sector is anticipated to be limited [2] - Trump's announcement on September 25 states that unless pharmaceutical companies are building factories in the US, patented drugs will face a 100% tariff starting October 1 [2] - The continuous upward momentum for innovative drugs is expected to primarily come from overseas partners pushing clinical developments for authorized pipelines [2]

Group 1: Semiconductor Industry - SMIC is the only domestic foundry with advanced process technology, benefiting from the explosion in AI chip demand and domestic substitution trends[1] - In 2025, advanced process revenue is expected to grow by 68% year-on-year, with plans to expand capacity to become the third-largest foundry globally[1] - The company's orders visibility has extended to 2026, indicating strong demand from key clients[1] Group 2: AI and Computing - Fourth Paradigm's platform sales are expected to turn from loss to profit, with a projected EPS increase from -0.6 to 0.4[1] - The overall valuation is currently around 4 times P/S, which is relatively low compared to domestic AI companies like SenseTime and US-based Palantir[1] - Risks include underperformance in AI technology development and market demand not meeting expectations[1] Group 3: Battery and Energy Storage - Zhongxin Innovation's revenue is projected to grow significantly, with a 101% increase in net profit expected in 2025[1] - The company is benefiting from high margins in overseas sales of power batteries and strong growth in commercial vehicles and energy storage batteries[1] - Risks include fluctuations in raw material prices and intensified competition in the industry[1] Group 4: Aerospace and Defense - AVIC Shenyang Aircraft's performance is expected to improve due to the implementation of fundraising projects aimed at enhancing research and production capabilities[1] - The company is focusing on modernizing weaponry and defense equipment, with a projected revenue increase of 13% in 2025[1] - Risks include legal penalties and management challenges affecting operational efficiency[1] Group 5: Pharmaceutical Sector - Zai Lab is advancing its commercialization efforts with three approved products, including a JAK inhibitor participating in the 2025 medical insurance negotiations[1] - The company is expected to accelerate product promotion, benefiting patients and enhancing revenue streams[1] - Risks include potential failures in new drug development and regulatory approval delays[1]

Core Viewpoint - Fosun Pharma is facing significant cash flow pressure, prompting the company to dispose of assets to improve liquidity and support its transition to innovative drug development [2][3][12]. Group 1: Asset Disposal - Fosun Pharma's subsidiary plans to transfer 100% equity of Shanghai Clone for a transaction price not exceeding 1.256 billion yuan [2]. - This transaction is part of a broader strategy, with the company having signed asset disposal agreements totaling over 2 billion yuan by mid-2025 [2]. - The asset transfer involves setting up a fund, with Fosun Pharma contributing 54.6 million yuan as a limited partner [2]. Group 2: Financial Pressure - As of mid-2025, Fosun Pharma's short-term borrowings reached 17.862 billion yuan, with total short-term debt amounting to 22.646 billion yuan, significantly exceeding cash reserves of 12.959 billion yuan [3][5]. - The company's financial expenses for the first half of 2025 amounted to 640 million yuan, the highest since its listing, consuming two-thirds of its net profit excluding non-recurring items [3][5]. Group 3: Debt Structure - Fosun Pharma's debt structure shows a high reliance on short-term debt, with 61% of its interest-bearing liabilities being short-term [5]. - The company's debt-to-asset ratio stands at 49.24%, higher than the average of 40% for A-share pharmaceutical companies [6]. - The cash coverage ratio is approximately 0.12, indicating a significant liquidity risk [7]. Group 4: Performance Metrics - For the first half of 2025, Fosun Pharma reported revenue of 19.514 billion yuan, a year-on-year decline of 4.63%, while net profit attributable to shareholders was 1.702 billion yuan, up 38.96% [9]. - The profit increase is largely attributed to asset disposal gains of 9.491 billion yuan, nearly doubling from the previous year [11]. - The company's core operating profit, reflected in the net profit excluding non-recurring items, fell by 23.39% to 961 million yuan [12]. Group 5: Innovation and Market Position - Fosun Pharma's innovative drug revenue growth is lagging behind industry leaders, with its PD-1 product "Hanshu" showing a 15% increase in revenue, compared to 28% for competitors [12][13]. - The proportion of revenue from innovative drugs is approximately 25%, lower than the 35% seen in leading companies like Heng Rui [13]. - The reliance on non-recurring investment income raises concerns about the sustainability of profit growth, as the company has not yet achieved scale effects in its high-margin innovative drugs [13].

Core Viewpoint - Hangzhou New Element Pharmaceutical Co., Ltd. is seeking an IPO on the Hong Kong Stock Exchange, focusing on innovative drugs for gout, but currently lacks revenue and has incurred significant losses [2][4]. Financial Performance - The company reported net losses of RMB 97 million, RMB 434 million, and RMB 165 million for the years 2023, 2024, and the first half of 2025, respectively, totaling nearly RMB 697 million in losses during the reporting period [2][4]. - Revenue during the same period was RMB 11.18 million, RMB 7.718 million, and RMB 1.813 million, primarily from other income sources such as government subsidies [4][5]. - As of June 30, 2025, the total accumulated loss was RMB 462 million, with over RMB 1 billion burned since the company's inception in 2012 [4][5]. Research and Development - R&D expenses were significant, amounting to RMB 177 million, RMB 338 million, and RMB 162 million for the years 2023, 2024, and the first half of 2025, respectively, representing a high percentage of the company's losses [5]. - The core product, ABP-671, is currently in clinical trials but has not yet entered Phase 3, with competition from other companies developing similar URAT1 inhibitors [2][7][10]. Market Potential - The global market for gout and hyperuricemia treatments is projected to grow from USD 3.2 billion in 2024 to USD 10.7 billion by 2033, with a compound annual growth rate of 14.2% [7]. - The number of hyperuricemia patients worldwide is expected to increase from approximately 1.1418 billion in 2024 to 1.3595 billion by 2033 [7]. Competitive Landscape - Several competitors are advancing in the development of URAT1 inhibitors, including products from companies like Hengrui Medicine and Yipin Pharmaceutical, which are already in Phase 3 clinical trials [10][11]. - ABP-671 is positioned as a potential first-in-class URAT1 inhibitor, targeting the treatment of gout and hyperuricemia with a focus on safety [7][10].